Trials / Completed
CompletedNCT02306291
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- GlycoMimetics Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate GMI-1271, a specific E-selectin antagonist, in acute myeloid leukemia in combination with standard agents used to treat this disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GMI-1271 | E-selectin antagonist |
| DRUG | Mitoxantrone | induction chemotherapy |
| DRUG | Etoposide | induction chemotherapy |
| DRUG | Cytarabine | induction chemotherapy |
| DRUG | Idarubicin | induction chemotherapy |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2017-12-01
- Completion
- 2018-05-01
- First posted
- 2014-12-03
- Last updated
- 2019-05-17
Locations
8 sites across 3 countries: United States, Australia, Ireland
Source: ClinicalTrials.gov record NCT02306291. Inclusion in this directory is not an endorsement.